Summary of main studies reporting complications related to VT ablation procedure assisted by haemodynamic support
| Author year . | n. patients . | Major bleeding . | Major vascular . | Limb ischaemia . | AKI . | CVA . | FU . | Outcomes . |
|---|---|---|---|---|---|---|---|---|
| VA-ECMO | ||||||||
| Baratto 2016 | 64 | 0 | 0 | 2 (3) | 4 (6) | 0 | 23 months | VT recurred in 33%, overall mortality was 12%, and rate of transplantation was 9%. |
| Enriquez 2018 | 18 | 3 (14) | 2 (10) | 0 | – | – | Median 10 days (range 1 days–27 months) | Seven patients survived >6 months. Five of these remained free of VT/VF and three ultimately received LVAD or heart transplant. |
| Di Monaco 2019 | 19 | 5 (26) | 3 (16) | 0 | 0 | 0 | 10 months | The procedural success rate was 68% and the Kaplan–Meier mortality rate was 21%. |
| Tandem heart | ||||||||
| Bunch 2012 | 13 | 1 (7) | 1 (7) | 0 | 0 | 0 | ||
| Impella | ||||||||
| Kusa 2017 | 109 | 7 (6) | 7 (6) | 0 | 0 | 0 | 7 months | VT, heart transplantation, or death occurred in 36% of the pLVAD vs. 26% of the non-pLVAD groups. |
| IABP | ||||||||
| Reddy 2014 | 22 | 3 (15) | 0 | – | – | – | 12 months | Mortality and VT recurrence were similar between IABP group and Impella and TandemHeart cohort. |
| Aryana 2017 | 115 | – | – | – | 26 (22) | – | 12 months | Catheter ablation of VT associated with mechanical support using PVAD vs. IABP was associated with reduced in-hospital cardiogenic shock, renal failure, length of stay, hospital readmissions, and mortality, but no difference in redo-VT ablation at 1 year. |
| Author year . | n. patients . | Major bleeding . | Major vascular . | Limb ischaemia . | AKI . | CVA . | FU . | Outcomes . |
|---|---|---|---|---|---|---|---|---|
| VA-ECMO | ||||||||
| Baratto 2016 | 64 | 0 | 0 | 2 (3) | 4 (6) | 0 | 23 months | VT recurred in 33%, overall mortality was 12%, and rate of transplantation was 9%. |
| Enriquez 2018 | 18 | 3 (14) | 2 (10) | 0 | – | – | Median 10 days (range 1 days–27 months) | Seven patients survived >6 months. Five of these remained free of VT/VF and three ultimately received LVAD or heart transplant. |
| Di Monaco 2019 | 19 | 5 (26) | 3 (16) | 0 | 0 | 0 | 10 months | The procedural success rate was 68% and the Kaplan–Meier mortality rate was 21%. |
| Tandem heart | ||||||||
| Bunch 2012 | 13 | 1 (7) | 1 (7) | 0 | 0 | 0 | ||
| Impella | ||||||||
| Kusa 2017 | 109 | 7 (6) | 7 (6) | 0 | 0 | 0 | 7 months | VT, heart transplantation, or death occurred in 36% of the pLVAD vs. 26% of the non-pLVAD groups. |
| IABP | ||||||||
| Reddy 2014 | 22 | 3 (15) | 0 | – | – | – | 12 months | Mortality and VT recurrence were similar between IABP group and Impella and TandemHeart cohort. |
| Aryana 2017 | 115 | – | – | – | 26 (22) | – | 12 months | Catheter ablation of VT associated with mechanical support using PVAD vs. IABP was associated with reduced in-hospital cardiogenic shock, renal failure, length of stay, hospital readmissions, and mortality, but no difference in redo-VT ablation at 1 year. |
Data are presented as number (%).
AKI, acute kidney injury; CVA, cerebrovascular accident; FU, follow-up; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; pLVAD, permanent LVAD; VA-ECMO, veno-arterial extracorporeal membrane oxygenator; VT, ventricular tachycardia.
Summary of main studies reporting complications related to VT ablation procedure assisted by haemodynamic support
| Author year . | n. patients . | Major bleeding . | Major vascular . | Limb ischaemia . | AKI . | CVA . | FU . | Outcomes . |
|---|---|---|---|---|---|---|---|---|
| VA-ECMO | ||||||||
| Baratto 2016 | 64 | 0 | 0 | 2 (3) | 4 (6) | 0 | 23 months | VT recurred in 33%, overall mortality was 12%, and rate of transplantation was 9%. |
| Enriquez 2018 | 18 | 3 (14) | 2 (10) | 0 | – | – | Median 10 days (range 1 days–27 months) | Seven patients survived >6 months. Five of these remained free of VT/VF and three ultimately received LVAD or heart transplant. |
| Di Monaco 2019 | 19 | 5 (26) | 3 (16) | 0 | 0 | 0 | 10 months | The procedural success rate was 68% and the Kaplan–Meier mortality rate was 21%. |
| Tandem heart | ||||||||
| Bunch 2012 | 13 | 1 (7) | 1 (7) | 0 | 0 | 0 | ||
| Impella | ||||||||
| Kusa 2017 | 109 | 7 (6) | 7 (6) | 0 | 0 | 0 | 7 months | VT, heart transplantation, or death occurred in 36% of the pLVAD vs. 26% of the non-pLVAD groups. |
| IABP | ||||||||
| Reddy 2014 | 22 | 3 (15) | 0 | – | – | – | 12 months | Mortality and VT recurrence were similar between IABP group and Impella and TandemHeart cohort. |
| Aryana 2017 | 115 | – | – | – | 26 (22) | – | 12 months | Catheter ablation of VT associated with mechanical support using PVAD vs. IABP was associated with reduced in-hospital cardiogenic shock, renal failure, length of stay, hospital readmissions, and mortality, but no difference in redo-VT ablation at 1 year. |
| Author year . | n. patients . | Major bleeding . | Major vascular . | Limb ischaemia . | AKI . | CVA . | FU . | Outcomes . |
|---|---|---|---|---|---|---|---|---|
| VA-ECMO | ||||||||
| Baratto 2016 | 64 | 0 | 0 | 2 (3) | 4 (6) | 0 | 23 months | VT recurred in 33%, overall mortality was 12%, and rate of transplantation was 9%. |
| Enriquez 2018 | 18 | 3 (14) | 2 (10) | 0 | – | – | Median 10 days (range 1 days–27 months) | Seven patients survived >6 months. Five of these remained free of VT/VF and three ultimately received LVAD or heart transplant. |
| Di Monaco 2019 | 19 | 5 (26) | 3 (16) | 0 | 0 | 0 | 10 months | The procedural success rate was 68% and the Kaplan–Meier mortality rate was 21%. |
| Tandem heart | ||||||||
| Bunch 2012 | 13 | 1 (7) | 1 (7) | 0 | 0 | 0 | ||
| Impella | ||||||||
| Kusa 2017 | 109 | 7 (6) | 7 (6) | 0 | 0 | 0 | 7 months | VT, heart transplantation, or death occurred in 36% of the pLVAD vs. 26% of the non-pLVAD groups. |
| IABP | ||||||||
| Reddy 2014 | 22 | 3 (15) | 0 | – | – | – | 12 months | Mortality and VT recurrence were similar between IABP group and Impella and TandemHeart cohort. |
| Aryana 2017 | 115 | – | – | – | 26 (22) | – | 12 months | Catheter ablation of VT associated with mechanical support using PVAD vs. IABP was associated with reduced in-hospital cardiogenic shock, renal failure, length of stay, hospital readmissions, and mortality, but no difference in redo-VT ablation at 1 year. |
Data are presented as number (%).
AKI, acute kidney injury; CVA, cerebrovascular accident; FU, follow-up; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; pLVAD, permanent LVAD; VA-ECMO, veno-arterial extracorporeal membrane oxygenator; VT, ventricular tachycardia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
